InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.14
(
0.01%
)
Bitcoin
66,307.09
(
-0.50%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: BTH post# 3867

Monday, 12/06/2010 12:18:11 PM

Monday, December 06, 2010 12:18:11 PM

Post# of 80490

It's not going to be in first-line setting until you go head-to-head in a large trial versus the current first-line setting drugs (just like Tasigna and Sprycel had to do with Glivec - and its a large trial ,with a lot of money).

Dr Kantarjian, the lead Ponatinib investigator, disagrees. I suggest you listen to yesterdays conference call.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up